CHEMM ChemoMetec

Storaktionærmeddelelse

Storaktionærmeddelelse

SELSKABSMEDDELELSE NR. 186

 

ChemoMetec A/S oplyser i medfør af §30 i lov om kapitalmarkeder, at SEB Investment Management AB har meddelt at have øge deres beholdning i ChemoMetec A/S til 871.255 aktier svarende til 5,01% af aktiekapitalen.





Eventuelle henvendelser:

Adm. direktør (CEO) Steen Søndergaard, ChemoMetec A/S

Telefon (+45) 4813 1020



Om ChemoMetec A/S

ChemoMetec udvikler, producerer og markedsfører analyseinstrumenter til celletælling og en lang række andre målinger. ChemoMetecs analyseinstrumenter markedsføres globalt inden for blandt andet pharma, biotek og landbrug. ChemoMetec har nogle af verdens førende medicinalvirksomheder blandt sine kunder, herunder Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca og Johnson & Johnson.

ChemoMetec blev etableret i 1997 og er børsnoteret på Nasdaq OMX Copenhagen. Se også

Vedhæftet fil

EN
14/02/2020

Underlying

CHEMMChemoMetec

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ChemoMetec

Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
CHEMM CHEMOMETEC

ChemoMetec (Buy, TP: DKK640.00) - Solid Q3, but with mixed elements

With c26% revenue growth, Q3 was stronger than expected, with a solid beat on recurring revenue lines, although instruments fell just shy of our forecast, mainly related to new product launches that, despite a significant rise in customer validations in progress, take time. The maintained guidance implies only c5% YOY growth in Q4, but we believe management is being conservative. We reiterate our BUY and DKK640 target price.

05/08/25 May 8, 2025 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Fortsat vækst i omsætning og driftsresultat

Fortsat vækst i omsætning og driftsresultat Periodemeddelelse for 3. kvartal 2024/25 (1. januar - 31. marts 2025) Fortsat vækst i omsætning og driftsresultat Omsætningen steg i 3. kvartal med 26% til DKK 124,2 mio. fra DKK 98,9 mio. i samme periode sidste år. Væksten var især drevet af salg af produkter knyttet til NC-platformen som følge af fremgang i aktiviteten hos kunder med igangværende kliniske forsøg og godkendte terapier. Udviklingen afspejler en fortsat fremgang i omsætningen af både instrumenter, forbrugsvarer og services. Lanceringen af de nye XcytoMatic-produkter forløber fort...

May 7, 2025 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Continued growth in revenue and operating profit

Continued growth in revenue and operating profit Trading statement for Q3 2024/25 (1 January - 31 March 2025) Continued growth in revenue and operating profit Revenue was up by 26% in the third quarter of 2024/25 to DKK 124.2 million from DKK 98.9 million in the year-earlier period. Growth was driven primarily by sales of products related to the NC platform, reflecting increased activity levels for customers with ongoing clinical trials and approved therapies. The Q3 performance reflected continued growth in sales of both instruments, consumables and services. The launch of the new XcytoM...

May 7, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
CHEMM CHEMOMETEC

ChemoMetec (Buy, TP: DKK640.00) - Likely solid Q3 but no pre-release

We previously expected ChemoMetec to have raised its full-year guidance ahead of the Q3 results, but assume the weaking USD and greater uncertainty from tariffs led it to refrain. We still expect a solid Q3, helped by new product launches, while in general we expect tariffs to have minimal effect on its costs, considering its location of production and high gross margin. We reiterate our BUY, but have lowered our target price to DKK640 (675).

05/04/25 May 4, 2025 1 EN
Free Trial
CHEMM CHEMOMETEC

ChemoMetec A S: 1 director

A director at ChemoMetec A S bought 865 shares at 574.030DKK and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

02/11/25 February 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch